Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TECL vs CURE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CURE Captures Overall Composite Edge (39.2 SELL vs 52.1 HOLD), While TECL Leads 1–0 on Growth & Valuation Pillars

CURE Overall Winner 6-Pillar Tally: TECL 1 – 0 CURE (5 Tie) Matrix Metrics: TECL 1 – 2 CURE

As of Nov 16, 2026, Direxion Daily Healthcare Bull 3X Shares (CURE) captures the overall head-to-head institutional edge over Direxion Daily Technology Bull 3x Shares (TECL) on higher Unified Composite conviction (39.2/100 SELL vs. 52.1/100 HOLD) after splitting the core matrix 2–1 (led by composite factor balance), while TECL wins 1–0 across the 6-pillar growth and valuation breakdown. TECL trades at $127.76 (N/M Forward P/E, N/A operating margin) versus CURE at $174.60 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While TECL currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. CURE 39.2/100 SELL), CURE captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: TECL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.5); meanwhile CURE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TECL vs CURE
TECL NYSE Arca
Direxion Daily Technology Bull 3x Shares
Institutional Equity
$127.76
-9.81% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 5.46β · 133% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 43.0 Fund 53.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.4%), weak momentum, RSI 34
RSI-14: 33.5 · SMA20: $167.77 · SMA50: $200.31
CURE NYSE Arca Head-to-Head Winner
Direxion Daily Healthcare Bull 3X Shares
Institutional Equity
$174.60
-1.57% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.83β · 62% Vol
Unified Composite Score
39.2 / 100 SELL
Tech 15.0 Fund 31.0 Flow 50.0 Mom 36.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.6% over 20 days), RSI 63
RSI-14: 62.6 · SMA20: $165.88 · SMA50: $145.13

6-Pillar Scorecard Institutional Category Breakdown (TECL 1 – 0 CURE)

Columns: Metric · TECL · CURE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TECL
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 92.4% (6th %ile) 45.1% (9th %ile)
Put/Call OI Skew 1.02x (Balanced) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TECL (1) vs CURE (2)
Institutional Metric TECL CURE Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
26% ($75–$275) 88% ($82–$188) Stronger Trend CURE
Beta / 30D Volatility
Risk Regime
5.46β · 133% Vol 0.83β · 62% Vol Lower Realized Risk CURE
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 39.2 / 100 (SELL) Higher Composite TECL
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CURE +50.46 pp
TECL: -32.3% · CURE: +18.16%
3M Horizon CURE +67.35 pp
TECL: -36.78% · CURE: +30.57%
6M Horizon CURE +129.95 pp
TECL: -32.08% · CURE: +97.87%
1Y Horizon CURE +59.86 pp
TECL: +1.33% · CURE: +61.19%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TECL vs CURE. Trailing 12-month operating profitability (TECL N/A vs CURE N/A) and valuation multiples (TECL N/M vs CURE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TECL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CURE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TECL BREAKDOWN
116d in phase · OBV NEUTRAL
Current IV 92.4%
IV Percentile 6th %ile
Put/Call OI Skew 1.02x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TECL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CURE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 45.1%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CURE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TECL Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CURE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TECL vs CURE Key Questions & Quantitative Answers

As of Nov 16, 2026, Direxion Daily Healthcare Bull 3X Shares (CURE) captures the overall head-to-head institutional edge over Direxion Daily Technology Bull 3x Shares (TECL) on higher Unified Composite conviction (39.2/100 SELL vs. 52.1/100 HOLD) after splitting the core matrix 2–1 (led by composite factor balance), while TECL wins 1–0 across the 6-pillar growth and valuation breakdown. TECL trades at $127.76 (N/M Forward P/E, N/A operating margin) versus CURE at $174.60 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While TECL currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. CURE 39.2/100 SELL), CURE captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: TECL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.5); meanwhile CURE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TECL and CURE split Growth & Scale metrics: TECL posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CURE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, TECL generates N/A in USD-normalized revenue versus N/A for CURE. In operating R&D and SG&A reinvestment, TECL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CURE.

TECL and CURE trade at balanced relative valuation multiples. TECL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CURE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TECL (N/A ROE) versus CURE (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, TECL carries 92.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 1.02x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (5.46β · 133% Vol realized risk). By comparison, CURE carries 45.1% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.83β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.